Dizzy spell

Dizzy spell Reaction Insights

The FDA Center for Veterinary Medicine database currently lists 25 adverse event reports that reference Dizzy spell as a reaction term, including 0 reports with a death outcome — a 0.0% case-fatality figure calculated across only those events where this reaction was coded. The reaction is indexed in the openFDA system under VeDDRA code 1424, the standardized veterinary dictionary used to normalize clinical signs across submitters. Because reports are voluntary and often describe multiple concurrent signs per animal, the volume here reflects reporting intensity rather than true incidence in the broader pet population.

Dizzy spell appears most frequently in reports for Human (25 reports) — with Human dominating at 25 entries. Within those species, the breeds most often named alongside this reaction are Unknown (25). These distributions are influenced both by underlying breed popularity and by how veterinarians and owners code a given clinical sign, so they should be interpreted as a reporting fingerprint rather than a pure susceptibility ranking.

The drugs most commonly co-reported with Dizzy spell are Gamithromycin 15% Injection (2 reports), Detomidine Hydrochloride (2 reports), Tildipirosin Injectable (2 reports), Moxidectin (2 reports), with Gamithromycin 15% Injection appearing alongside this reaction in 2 submissions. Co-reporting does not establish that any specific product caused the reaction — FDA CVM data captures temporal association only. The value of these aggregates is in flagging which therapeutic classes appear repeatedly alongside a given clinical sign, so owners and veterinarians can ask targeted questions about medications currently in use.